Ichnos Glenmark Innovation presents first clinical data from phase 1 study of Trispecific TREAT Antibody, ISB 2001
Express Pharma
DECEMBER 9, 2024
ISB2001 Phase 1 Dose Escalation Study Design The Phase 1, first-in-human, open-label study is evaluating the safety and anti-myeloma activity of ISB2001 in patients with RRMM. The post Ichnos Glenmark Innovation presents first clinical data from phase 1 study of Trispecific TREAT Antibody, ISB 2001 appeared first on Express Pharma.
Let's personalize your content